Evidence map›Paper›PMID 41945271›Full record

ArticleEJNMMI research2026

[

Christel Hermann Kamani, Julien Costes, Maxime Panchaud, Kilian Casagrande, Giorgio Treglia, Mario Jreige, Marie Nicod Lalonde, Niklaus Schaefer, Judith Delage, John O Prior

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in EJNMMI research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Christel Hermann KamaniDepartment of Nuclear Medicine and Molecular Imaging, CHUV, Rue du Bugnon 46, 1011, Lausanne, Switzerland.
Julien CostesDepartment of Nuclear Medicine and Molecular Imaging, CHUV, Rue du Bugnon 46, 1011, Lausanne, Switzerland.
Maxime PanchaudNeuchatel Hospital Network, Rue de la Maladière 45, 2000, Neuchâtel, Switzerland.
Kilian CasagrandeDepartment of Nuclear Medicine and Molecular Imaging, CHUV, Rue du Bugnon 46, 1011, Lausanne, Switzerland.
Giorgio TregliaUniversity of Lausanne, Lausanne, Switzerland.
Mario JreigeDepartment of Nuclear Medicine and Molecular Imaging, CHUV, Rue du Bugnon 46, 1011, Lausanne, Switzerland.
Marie Nicod LalondeDepartment of Nuclear Medicine and Molecular Imaging, CHUV, Rue du Bugnon 46, 1011, Lausanne, Switzerland.
Niklaus SchaeferDepartment of Nuclear Medicine and Molecular Imaging, CHUV, Rue du Bugnon 46, 1011, Lausanne, Switzerland.
Judith DelageDepartment of Nuclear Medicine and Molecular Imaging, CHUV, Rue du Bugnon 46, 1011, Lausanne, Switzerland.
John O PriorDepartment of Nuclear Medicine and Molecular Imaging, CHUV, Rue du Bugnon 46, 1011, Lausanne, Switzerland. John.Prior@chuv.ch.ORCID http://orcid.org/0000-0003-1429-1374

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundLabelling WBC with [18F]FDG may be an alternative for accurate infection diagnosis, combining the excellent sensitivity of [18F]FDG with the excellent specificity of WBC-labelled SPECT/CT. We aim to investigate the feasibility, safety and accuracy of [18F]FDG-labelled WBC in patients with suspected infectious disease.

resultsScans were performed at 131 ± 13 min and 201 ± 16 min after [18F]FDG-labelled WBC administration. 14 identified lesions were follow-up. [18F]FDG-labelled WBC PET/CT yielded a sensitivity / specificity of 82% / 100%. False negative lesions were localized in axial and proximal skeleton. SUVmax@2h and SUVmax@3h for infected lesions were 10.4 ± 8.8 and 13.9 ± 12.3. aSUV and rSUV values for infected lesions were 3.5 ± 4.3 and 34.2 ± 29.1 Radiolabelling efficiency was 74.8 ± 19.4% (84.9 ± 5.34% vs. 57.9 ± 22.3%, p < 0.025 in diabetic vs. non-diabetic). The dose to the operator were 39.3 ± 11.8 µSv for the axial body and 69.1 ± 26.2 µSv for the extremities.

conclusionsAssessing the dynamic of [18F]FDG-labelled WBC is feasible and yielded a very good diagnostic performance, however with some limitation for lesion of the axial skeleton and the reticuloendothelial system. Moreover, the procedure is operator and patient safe. Improvement in shielding during radiolabelling as well as further investigations with larger population are still needed.

Indexed as

[18F]FDG-labelled WBCDiagnostic performanceInfectious diseasePET/CT

Identifiers

PMID41945271
PMCPMC13187070

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.